

EUROPLAN

European Project for Rare Diseases National Plans Development

Coordinated by the Italian National Centre for Rare Diseases

Italian National Institute of Health

2012-2015



INDICATORS SELECTION

according to the Delphi technique (EUROPLAN “A”):
presentation of results

Rita M. Ferrelli, Amalia Egle Gentile, Marta De Santis

EUROPLAN 2012-2015 Coordinating Team

Italian National Centre for Rare Diseases
Italian Institute of Health
Rome, Italy



Two processes for selecting a limited number of indicators:

- **Delphi process:**
 - *participants:* MoH representatives of 27 MS, 10 EURORDIS Advisors and 4 experts, *carried out by ISS (EUROPLAN “A”).*
- **EURORDIS approach:**
 - participants:* 7 EURORDIS Advisors in conjunction with their MoH lead contacts on NP/NS,
carried out by EURORDIS (EUROPLAN “B”).

The results of both processes are discussed during this meeting

THE DELPHI PROCESS

- A qualitative research technique for consensus building
- Communication is organised in a group of experts in order to achieve their opinion in a systematic way and to group subjective judgments
- Every expert can express his/her own opinion anonymously

THE PROCEDURE

Delphi proceeds in a series of rounds

Round 1: Experts are invited to provide opinions on a specific matter, based on their knowledge and experience. These opinions are grouped together under a limited number of headings and statements drafted for circulation to all participants on a questionnaire;

Round 2: Participants rank their agreement with each statement in the questionnaire. The rankings are summarised and included in a repeat version of the questionnaire;

Round 3: Participants rerank their agreement with each statement in the questionnaire, with the opportunity to change their score in view of the group's response. The rerankings are summarised and assessed for degree of consensus: if an acceptable degree of consensus is obtained the process may cease, with final results fed back to participants; if not, the third round is repeated.

METHOD

- **PARTICIPANTS**


MoH representatives from 27 MS, + MoH representatives from Norway and Croatia, 10 EURORDIS Advisors, and 4 experts in RD and indicators development.

- **CRITERIA FOR SELECTING INDICATORS:**

USEFULNESS and FEASIBILITY

- **METHODOLOGICAL HOMOGENEITY**

we prepared an *USER MANUAL* to facilitate the process and to ensure homogeneity.



EUROPLAN

European Project for Rare Diseases National Plans Development

Coordinated by the Italian National Centre for Rare Diseases

Italian National Institute of Health

2012-2015

HOME THE PROJECT PARTNERS EVENTS NATIONAL PLANS ONGOING ACTIVITIES DOCUMENTS MEMBERS AREA CONTACT

MEMBERS AREA


[Home](#) > Members area

Members area

- ▶ [European Indicators on National plans for Rare Diseases](#)
- ▶ [EUROPLAN 2012-2015 - Capacity Building Community](#)

The dedicated website was accessible in the private area of the EUROPLAN website

www.europlanproject.eu



EUROPLAN

European Project for Rare Diseases National Plans Development
Project coordinated by the Italian National Centre for Rare Diseases
Italian National Institute of Health

2012-2015

Username:

Password:

Enter

PARTICIPANTS

- **26 EU MS** MoH Representatives (instead 27)
- **2 non-EU Countries** MoH Representatives
- **4 Experts**
- **6 EURORDIS Advisors** (out of a total of 10)

...about
27 EU MS...



- **23** provided all data
- **3** provided data partially
- **1** did not participate (Germany)

| | Country | AREA 1 | AREA 2 | AREA 3 | AREA 4 | AREA 5 | AREA 6 | AREA 7 | Status |
|-------------------|----------------------------------|--------|--------|--------|--------|--------|--------|----------|---|
| 26 EU MS | Austria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Belgium | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Bulgaria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Cyprus | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Czech Republic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Denmark | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Estonia | ✓ | ✓ | x | ✓ | ✓ | ✓ | ✓ | Incomplete |
| | Finland | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | France | ✓ | ✓ | ✓ | ✓ | x | ✓ | ✓ | Incomplete |
| | Greece | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Hungary | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Ireland | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Italy | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Latvia | ✓ | ✓ | ✓ | ✓ | x | ✓ | ✓ | Incomplete |
| | Lithuania | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Luxembourg | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Malta | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Netherlands | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Poland | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Portugal | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| Romania | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE | |
| Slovakia | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE | |
| Slovenia | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE | |
| Spain | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE | |
| Sweden | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE | |
| United Kingdom | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE | |
| plus | Germany | | | | | | | | This Country did not participate: too early |
| Non EU | Croatia | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Norway | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | 4 Experts (France, Italy, Spain) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| EURORDIS Advisors | Belgium, Denmark, Portugal | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Finland, Sweden | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | France, Switzerland | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Georgia, Russia, Ukraine | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Hungary, Romania, Slovakia | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |
| | Italy, Greece, Spain | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | COMPLETE |


RESULTS

- **PARTICIPANTS** respondent rate = **100%** (38/38).
- **COMPLETED AREAS** rate = **99%** (265/268).

26 MS (instead of 27)

- One Country (*Germany*) deemed the indicators process selection to be in a early stage (as no formal consensus on the different actions has been reached by the steering committee yet) and decided not rake part into the process.
 - Three Countries (*Estonia, France, and Latvia*) answered partially in some areas. The incomplete areas were not evaluated.
 - EURORDIS participated with 6 Advisors (out of a total = 10), selected upon a criteria of personal availability.
- Data analysis reports the mean, median and range of the values.
 - Only the highest median has been taken into account for selecting the indicators.

The highest scored



■ Feasibility

■ Usefulness

Highest scored

PRELIMINARY OBSERVATIONS

- The Delphi process allowed for a selection of a limited number of indicators for national plans on rare diseases
- The literature recommends that the results should, when possible, be matched to observable events (pilot study in EUROPLAN II)

Working Group

- **Domenica Taruscio** - *EUROPLAN Leader*
- **Marta De Santis, Rita M. Ferrelli, Amalia Egle Gentile** - *EUROPLAN 2012-2015 Coordinating Team*
- **Manuel Posada** - *Institute of Rare Diseases Research, Instituto de Salud Carlos III*
- **Luciano Vittozzi** - *Italian National Centre for Rare Diseases Italian National Institute of Health*

“Overlapping” indicators between ISS & EURORDIS= 20 (DRAFT)

| | USEFULNESS | FEASIBILITY |
|---|------------|-------------|
| 1.1 - Existence of Regulations/Laws that support the creation and development of a RD plan | 9,5 | 9 |
| 1.4 - Existence of an expert advisory committee | 9,5 | 10 |
| 1.7 - Budget of plan/strategy | 9 | 9 |
| 2.1 - Adoption of the EC RD definition   | 9 | 10 |
| 2.2 - Type of classification used by the health care system | 10 | 9 |
| 2.4 - Registering activity | 9 | 8 |
| 3.9 - There are specific public funds allocated for RD research | 9 | 8 |
| 3.10 - Funds specifically allocated for RD research actions/projects per year since then plan started | 9 | 8 |
| 4.1 - Existence of a policy for establishing centres of expertise at the national/regional level | 10 | 10 |
| 4.2 - Number of centres of expertise adhering to the policy defined in the country | 8 | 9 |
| 4.5 - Participation of national or regional centres of expertise into European reference networks | 9 | 9 |
| 5.1 - Existence of a comprehensive national and/or regional RD information system supported by the government | 10 | 9 |
| 5.2 - Help lines for professionals + 6.10 - Availability of Help line for RD | 9 | 9 |
| 5.3 - Clinical guidelines | 10 | 8,5 |
| 5.13 - Existence of a governmental program for compassionate use for Rare Diseases | 9 | 9 |
| 6.5 - Permanent and official patients’representatives in plan development, monitoring and assessment | 10 | 10 |
| 6.15 - Existence of programmes to support integration of RD patients in their daily life | 9 | 8 |
| 7.1 - Existing policy/decision to ensure long-term sustainability of the RD plan /strategy   | 10 | 9 |
| 7.2 - Amount of funds allocated for ensuring RD plan /strategy sustainability | 9 | 8 |
| 7.3 - Existing policy/decision to ensure the contribution to support RD European infrastructure   | 9 | 9 |

REFERENCES

- Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ* 1995; 311: 376-380.
- Linstone HA. The Delphi technique. In: Fowles RB, ed. *Handbook of futures research*. Westport, CT: Greenwood, 1978.
- Moscovice I, Armstrong P, Shortell S. Health services research for decisionmakers: the use of the Delphi technique to determine health priorities. *Y Health Polit Policy Law* 1988;2:388-410.
- Oranga HM, Nordberg E. The Delphi panel method for generating health information. *Health Policy and Planning*. 1993;8:405-12.
- Pill J. The Delphi method: substance, context, a critique and an annotated bibliography. *Socio-Economic Planning Science* 197 1;5:57-71.
- Rowe and Wright. *Expert Opinions in Forecasting. Role of the Delphi Technique*. In: Armstrong (Ed.): *Principles of Forecasting: A Handbook of Researchers and Practitioners*, 2001. Boston: Kluwer Academic Publishers.
- Skulomosky G, Hartman FT, Krahn J. The Delphi method for graduate research. *Journal of Information Technology Education* 2007; 6:1-21.
- Wiener B, Chacko S et al. Delphi survey of research priorities. *J Nurs Manag* 2009; 17:532-8.